Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?
Graphical Abstract Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.
Gespeichert in:
| Veröffentlicht in: | EMBO reports 2023-02, Vol.24 (2) |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | |
| container_title | EMBO reports |
| container_volume | 24 |
| creator | De Luca, Michele Cossu, Giulio |
| description | Graphical Abstract
Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market. |
| doi_str_mv | 10.15252/embr.202256661 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9900339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2772932905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c249t-b81bbd0f80229c908073fe705789fbbfaffa107647ad98301c6f6396d27032163</originalsourceid><addsrcrecordid>eNp1kM1LAzEQxYMotlbPXhc8bztJdvNxEaT4BQUvCt5Cspu0KdtNTbaF_veubal48DQD895vHg-hWwxjXJKSTOzKxDEBQkrGGD5DQ1wwmVPMxflxJwR_DtBVSksAKCUXl2hAWSkJLvAQsWlIXabbOtNb7RttfOO7XRZc1oatbbLKNs3-PLetzbqFjXrtbbpGF043yd4c5wh9PD2-T1_y2dvz6_RhllekkF1uBDamBif6gLKSIIBTZzmUXEhnjNPOaQycFVzXUlDAFXOMSlYTDpRgRkfo_sBdb8zK1pVtu6gbtY5-peNOBe3V30vrF2oetkpKAEplD7g7AmL42tjUqWXYxLbPrAjnRFIioexVk4OqiiGlaN3pAwa1L1r9FK1ORfcOODhSr2znNv5y_7N8A9Mfft8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2772932905</pqid></control><display><type>article</type><title>Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>De Luca, Michele ; Cossu, Giulio</creator><creatorcontrib>De Luca, Michele ; Cossu, Giulio</creatorcontrib><description>Graphical Abstract
Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.</description><identifier>ISSN: 1469-221X</identifier><identifier>EISSN: 1469-3178</identifier><identifier>DOI: 10.15252/embr.202256661</identifier><identifier>PMID: 36592141</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>EMBO08 ; EMBO16 ; EMBO49 ; Gene therapy ; Life Sciences ; Science & Society</subject><ispartof>EMBO reports, 2023-02, Vol.24 (2)</ispartof><rights>The Author(s) 2022</rights><rights>2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 The Authors. Published under the terms of the CC BY NC ND 4.0 license.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c249t-b81bbd0f80229c908073fe705789fbbfaffa107647ad98301c6f6396d27032163</cites><orcidid>0000-0001-5863-9593 ; 0000-0002-0850-8445</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900339/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900339/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,41125,42194,51581,53796,53798</link.rule.ids></links><search><creatorcontrib>De Luca, Michele</creatorcontrib><creatorcontrib>Cossu, Giulio</creatorcontrib><title>Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?</title><title>EMBO reports</title><addtitle>EMBO Rep</addtitle><description>Graphical Abstract
Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.</description><subject>EMBO08</subject><subject>EMBO16</subject><subject>EMBO49</subject><subject>Gene therapy</subject><subject>Life Sciences</subject><subject>Science & Society</subject><issn>1469-221X</issn><issn>1469-3178</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp1kM1LAzEQxYMotlbPXhc8bztJdvNxEaT4BQUvCt5Cspu0KdtNTbaF_veubal48DQD895vHg-hWwxjXJKSTOzKxDEBQkrGGD5DQ1wwmVPMxflxJwR_DtBVSksAKCUXl2hAWSkJLvAQsWlIXabbOtNb7RttfOO7XRZc1oatbbLKNs3-PLetzbqFjXrtbbpGF043yd4c5wh9PD2-T1_y2dvz6_RhllekkF1uBDamBif6gLKSIIBTZzmUXEhnjNPOaQycFVzXUlDAFXOMSlYTDpRgRkfo_sBdb8zK1pVtu6gbtY5-peNOBe3V30vrF2oetkpKAEplD7g7AmL42tjUqWXYxLbPrAjnRFIioexVk4OqiiGlaN3pAwa1L1r9FK1ORfcOODhSr2znNv5y_7N8A9Mfft8</recordid><startdate>20230206</startdate><enddate>20230206</enddate><creator>De Luca, Michele</creator><creator>Cossu, Giulio</creator><general>Nature Publishing Group UK</general><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5863-9593</orcidid><orcidid>https://orcid.org/0000-0002-0850-8445</orcidid></search><sort><creationdate>20230206</creationdate><title>Cost and availability of novel cell and gene therapies</title><author>De Luca, Michele ; Cossu, Giulio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c249t-b81bbd0f80229c908073fe705789fbbfaffa107647ad98301c6f6396d27032163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>EMBO08</topic><topic>EMBO16</topic><topic>EMBO49</topic><topic>Gene therapy</topic><topic>Life Sciences</topic><topic>Science & Society</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Luca, Michele</creatorcontrib><creatorcontrib>Cossu, Giulio</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>EMBO reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Luca, Michele</au><au>Cossu, Giulio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death?</atitle><jtitle>EMBO reports</jtitle><stitle>EMBO Rep</stitle><date>2023-02-06</date><risdate>2023</risdate><volume>24</volume><issue>2</issue><issn>1469-221X</issn><eissn>1469-3178</eissn><abstract>Graphical Abstract
Advanced gene and cellular therapies risk a second “valley of death” due to their high costs and low patient population. As these are life‐saving therapies, measures are urgently needed to prevent their withdrawal from the market.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>36592141</pmid><doi>10.15252/embr.202256661</doi><orcidid>https://orcid.org/0000-0001-5863-9593</orcidid><orcidid>https://orcid.org/0000-0002-0850-8445</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1469-221X |
| ispartof | EMBO reports, 2023-02, Vol.24 (2) |
| issn | 1469-221X 1469-3178 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9900339 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Wiley Online Library All Journals; PubMed Central; Springer Nature OA/Free Journals |
| subjects | EMBO08 EMBO16 EMBO49 Gene therapy Life Sciences Science & Society |
| title | Cost and availability of novel cell and gene therapies: Can we avoid a catastrophic second valley of death? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T17%3A07%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20and%20availability%20of%20novel%20cell%20and%20gene%20therapies:%20Can%20we%20avoid%20a%20catastrophic%20second%20valley%20of%20death?&rft.jtitle=EMBO%20reports&rft.au=De%20Luca,%20Michele&rft.date=2023-02-06&rft.volume=24&rft.issue=2&rft.issn=1469-221X&rft.eissn=1469-3178&rft_id=info:doi/10.15252/embr.202256661&rft_dat=%3Cproquest_pubme%3E2772932905%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2772932905&rft_id=info:pmid/36592141&rfr_iscdi=true |